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Abstract One of the most fundamental goals of the study
of human genetics was to determine the relationship between
genomic variation and human disease. The effects of large-
scale structural variation, such as aneuploidy and other
cytogenetically visible imbalances, as well as sequence-
level variation, have been studied for several decades.
However, compared to these, the impact of submicroscopic
copy number variants (CNV) has only recently been appre-
ciated. Despite this, lessons learned from the study of CNVs
have already proven significant and broadly applicable.
From expanding the concept of normal human variation to
providing concrete examples of the utility of genomics in
clinical care and challenging notions of the genetic archi-
tecture of complex disease, CNVs have provided valuable
insights into the genomics of human health and development.
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Introduction
The physical map and DNA sequence derived from the
Human Genome Project [1] revolutionized cytogenetic
testing by providing the ability to detect submicroscopic
imbalances across the genome. Technologic advances,
namely the advent of comparative genomic hybridization,
allowed for the detection of CNVs in the research setting in
the 1990s [2–5]; subsequent improvements in the test
design gave chromosomal microarray (CMA) more utility
in the clinical diagnostic setting. These advances included
the addition of large genomic clones (e.g., bacterial artifi-
cial chromosomes, or BACs) to allow for the detection of
single-copy losses or gains [6] followed by the replacement
of genomic clones with synthetic oligonucleotides [7] for
genome-wide interrogation and more precise identification
of breakpoints. By the late 2000s, oligonucleotide CMA
designs were implemented for clinical testing that included
both targeted (representing known clinically relevant
regions) and genome-wide backbone coverage [8]. This
design schema enabled CMA to identify all imbalances
detectable by karyotype plus submicroscopic CNVs, thus
surpassing the diagnostic yield of a G-banded karyotype
[9••].
At the time CMA was first being implemented in the
clinic, the role of CNVs in human disease was still largely
unclear—the mechanisms of formation were not com-
pletely understood, and the clinical significance of many
novel findings was frustratingly uncertain. Over time,
through intense examination and data sharing, the roles,
mechanisms, and significance of CNVs have become
clearer, laying the foundation for discovery in the next-
generation sequencing era.
Expanding the Scope of Normal Human Variation
Although structural variation in normal individuals has
been appreciated for decades at the microscopic level [10],
the extent to which the human genome was subjected to
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submicroscopic copy number variation was not realized
until 2004. Studies using CMA technology revealed CNVs
throughout the genomes of normal individuals, several of
which were present in [10 % of the individuals studied
[11, 12]. Indeed, CNVs are thought to account for *1 % of
the variation between two individuals; in contrast, single
nucleotide polymorphisms (SNPs) are thought to account
for approximately 0.1 % [13].
Studies documenting common areas of normal structural
variation continue to serve as valuable resources for those
evaluating the clinical significance of CNVs; it has his-
torically been assumed that CNVs identified in ‘‘normal’’
populations could be classified as ‘‘likely benign’’ or
‘‘benign.’’ Early guidelines for the clinical interpretation of
CNVs proposed that CNVs inherited from reportedly nor-
mal parents could ‘‘probably’’ be considered benign [9••].
However, assumptions such as these should be made with
caution and in the context of the family’s clinical presen-
tation. There are many examples of ‘‘pathogenic’’ CNVs
exhibiting reduced penetrance and/or variable expressivity,
and many instances in which a more severely affected child
has inherited a CNV from a seemingly normal parent. The
22q11.2 deletion (del) syndrome is a classic example of
this phenomenon [14], though few would argue about the
pathogenicity of this particular CNV.
A more fitting example might be del 15q11.2, including
the region between breakpoints (BP) 1–2. A number of case–
control studies have demonstrated that this deletion is enri-
ched in cases as compared to controls [15•–17]. Nonetheless,
the fact that it has been observed in control individuals and
unaffected relatives, coupled with the broad spectrum of
associated phenotypes (developmental delay [15•, 16],
schizophrenia [18], epilepsy [17, 19], etc.), has anecdotally
resulted in some hesitances to classify it as ‘‘pathogenic.’’
However, a recent study of control individuals found to carry
CNVs previously associated with neuropsychiatric disor-
ders, such as autism spectrum disorders (ASD) and schizo-
phrenia (including del 15q11.2 BP 1–2), showed that these
individuals performed at a level between that of schizo-
phrenic patients and population controls on a series of cog-
nitive measures, even though they had never received a
formal neuropsychiatric diagnosis [20••]. This observation
gives more credence to the interpretation of del 15q11.2 as
pathogenic with variable expressivity but, more importantly,
puts forth the idea that CNVs observed in seemingly normal
populations could indeed be conferring varying levels of
clinical effects, challenging the notion that variation found in
normal populations is predominantly benign. Therefore,
quantitative measures assessing neurodevelopmental phe-
notypes, such as cognition and behavior, may be more
helpful than broad categorical diagnoses (e.g., affected ver-
sus unaffected) when trying to establish the effect of geno-
mic variation [21].
A Paradigm Shift in Clinical Genetic Care
While certain CNVs are common within the ‘‘normal’’
population, others have been associated with disorders of
human health and development. Several genomic disorders
were identified with the advent of high-resolution chro-
mosome banding and fluorescence in situ hybridization
(FISH) technologies (Prader Willi/Angelman syndromes
[OMIM 176270/105830]; Miller-Dieker syndrome [OMIM
247200], Williams-Beuren syndrome [OMIM 194050],
etc.); however, the widespread use of CMA allowed for the
identification of numerous others at a remarkable pace [22–
26], often before a clear phenotypic picture had emerged.
As CMA design evolved to include targeted coverage of
clinically relevant regions and uniformly spaced backbone
coverage throughout the euchromatic regions of each
chromosome [8], CMA truly became a ‘‘genome-wide’’
assay. Although the G-banded karyotype was essentially
the first genome-wide assay in the most basic sense of the
term, CMA provided clinicians with a way to interrogate
the entire genome with a single, high-resolution assay.
Before this, genetic diagnoses were made based upon a
clinician’s observations of the patients presenting pheno-
type, and that phenotype’s consistency (or lack thereof)
with previously described genetic syndromes. Even with
the advent of sequence-based genetic testing, diagnoses
still relied on the clinician’s ability to deduce a plausible
set of differential diagnoses from the observed phenotype
and select the correct gene(s) to test, if clinically available.
Diagnostic testing under this paradigm required an a priori
idea of the underlying diagnosis and causative mechanism,
and testing each of the possible differential diagnoses was
undertaken separately. This approach was ineffective if the
suspected clinical diagnosis was incorrect or if the causa-
tive mechanism was unknown, leaving many patients
without a confirmed genetic diagnosis. It naturally followed
that those presenting with classical symptoms of well-
described genetic conditions had the best chance of
obtaining a diagnosis, while those with more ambiguous
symptoms or with rarely or never described conditions
remained undiagnosed or were misdiagnosed.
With CMA, no priori predictions of the patient’s diagnosis
are required, making the test particularly appealing for use in
those with non-specific symptoms, including developmental
delays, ASD, and congenital anomalies. By evaluating the
entire genome at once, both previously described syndromes
and novel etiologies could be identified. CMA becoming
recognized as a first-tier test for these groups of individuals
[27•] represented a paradigm shift in the diagnosis of genetic
disorders from ‘‘phenotype-first,’’ where clinicians used the
patient’s phenotype to guide decisions about which genetic
tests to order, to ‘‘genotype-first,’’ where clinicians used the
patient’s genotype, to guide their evaluation and management.
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CMA results, expressed in specific genomic coordinates,
also afforded clinicians with the ability to truly integrate
information garnered from personal genotype into medical
care. With more precise breakpoints for patients’ CNVs,
laboratories and clinicians can determine which genes are
involved in a CNV. Using available information about the
gene(s) phenotypic effects and dosage sensitivity, one can
extrapolate which of the patient’s presenting features could
be explained by the CNV, as well as health issues that the
patient could be at risk for in the future. Such health issues
may be associated with specific management recommen-
dations which could be implemented for a patient before
they were even symptomatic.
For example, an individual could present to medical
attention for developmental delay, and CMA results dem-
onstrate a large deletion on chromosome 7q involving the
KCNH2 gene associated with long-QT syndrome 2 (OMIM
613688) [28]. Such results would indicate that the indi-
vidual is at high risk for developing this disorder, which is
associated with cardiac arrhythmia and sudden death. A
referral to a cardiologist is then warranted for evaluation
and management of this risk, something that was likely not
expected in the context of the original presenting symptoms
(i.e., an incidental finding). Examples such as this one are
not infrequent, particularly given the number of potentially
actionable genes with dosage sensitivity, such as cancer
predisposition genes, which are covered as part of standard
array designs. One study using data from the International
Standards for Cytogenomic Arrays (ISCA) consortium
database estimated that *7 % of reported cases involved a
region of the genome associated with some types of pub-
lished medical management recommendations, demon-
strating the clinical actionability of CMA test results [29].
Key Contributor to Complex Conditions
Additionally, CNVs have been identified as important con-
tributors to complex conditions, such as ASD. Heritability
estimates have varied for ASD, but have been reported as
high as 90 % [30]. Identifying the genetic basis of these types
of conditions through traditional methods (such as linkage
analysis) has been challenging due to their extensive genetic
and phenotypic heterogeneity. Linkage studies identified
several SNPs associated with ASD, but all with relatively
low effect size [30]. Likewise, genome-wide association
studies (GWAS) undertaken to identify common risk vari-
ants have been largely unsuccessful. Although several
common risk variants have been identified, the results have
been difficult to replicate and were associated with odds
ratios less than 1.23 [1, 32], making it clear that these
methods were missing variants of moderate–high effect.
As these populations began to be evaluated for CNVs, the
significant contribution of structural variation to ASD became
apparent. Many CNVs have been identified among individ-
uals with ASD [33–35], and some recurrent CNVs (mediated
by segmental duplications) have even reached statistical sig-
nificance in large-scale case–control studies [34]. Although
none of these CNVs individually account for more than 1 %
of ASD cases, as a group, structural variants play a significant
role in the development of this disorder, providing a genetic
diagnosis in 5–10 % of cases. CNVs have been reported to
confer more than 3 times the level of risk attributed to SNPs
identified through GWAS [32, 36].
Similar observations have been made in other complex
disorders, such as intellectual disability, schizophrenia, epi-
lepsy, and cardiac defects (presented in this issue). Interest-
ingly, many of the same CNVs are being identified among
phenotypes which were previously considered distinct. These
observations have led some to consider whether these phe-
notypes may actually represent aspects of an etiologically
related continuum, such as the developmental brain dysfunc-
tion model described for neurodevelopmental disorders [21].
Conclusion
Identifying an underlying genetic etiology for any human
phenotype is invaluable, both to the individual patient and
to the research community as a whole. For the individual
patient, receiving a specific genetic diagnosis can end the
taxing diagnostic odyssey, contribute to current and future
medical management, and impact family planning consid-
erations. For the research community, molecularly defining
previously uncharacterized disorders provides the oppor-
tunity to learn more about gene function, gene–gene
interactions, and genotype–phenotype correlations, which
will ultimately lead to targeted therapeutics.
The lessons learned from CMA and copy number vari-
ation have contributed greatly to both the ability to diag-
nose individuals and to the knowledge base surrounding the
mechanisms of human disease. As whole-exome and
whole-genome technologies become more accessible, the
cycle of discovery and knowledge assimilation will con-
tinue to accelerate; new variants will be discovered, new
mechanisms will be deduced, and our perception of clinical
genomics will evolve. These types of genome-wide assays
have already and will continue to identify genomic variants
with immediately appreciable effects on human health and
development. However, they will also continue to identify
variants of uncertain clinical significance, as our ability to
identify variation is currently beyond our ability to accu-
rately interpret its possible phenotypic consequences.
Various databases designed to catalog and make publicly
available structural variation data from both normal and
affected populations (Database of Genomic Variation [37]
for normal populations; the ISCA Consortium [9••],
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DECIPHER [38], ECARUCA [39], etc. for affected popula-
tions) have been established. These databases continue to
serve as valuable resources for laboratories and clinicians as
they interpret CNVs observed in patients on a daily basis. As
technologic advances move toward the ability to detect both
structural- and sequence-level data from the same testing
platform, similar resources are needed to make information
about both types of variation readily accessible to both the
research and clinical communities. ClinVar is a resource
housed within the National Center for Biotechnology Infor-
mation (NCBI) that collects information about the relation-
ships between human variation (both structural and sequence
level) and human disease. Large-scale efforts are underway
through the International Collaboration for Clinical Genomics
(ICCG) [40] to facilitate the submission of clinical laboratory
data from CMA- and sequencing-based tests into this database,
with plans to ultimately include whole-exome and whole-
genome data. These efforts are part of a larger collaboration,
the Clinical Genomics Resource (ClinGen), which aims to use
this information, coupled with manual and machine learning-
based curation efforts, to create a ‘‘clinical genome,’’ or cat-
alog of variants known to be relevant to clinical care.
The scope of knowledge regarding the nature of struc-
tural variation and its relationship to human health has
expanded dramatically over the last several decades; with
increased usage of whole-genome and whole-exome
sequencing, it is expected that the same will occur for
sequence-level variation. Increased data sharing and col-
laboration will lead to substantial progress in understand-
ing the relationships between variants and disease, making
personalized genomic medicine a reality.
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